A treatment designed to slow the loss of the body’s remaining insulin-producing capacity in some children with type 1 diabetes has received an expanded indication from the United States Food and Drug Administration. The FDA announced on June 15, 2026, that it had granted accelerated approval to teplizumab, marketed as Tzield, for certain paediatric patients aged 8 to 17 who have recently been diagnosed with Stage 3 type 1 diabetes. The approval is an important development in disease management, but it does not mean the condition has been cured. The FDA’s official announcement sets out the indication and evidence.

Blood glucose meter used in diabetes care
A blood glucose meter used in diabetes care. Credit: Fatimah Bello, CC0, via Wikimedia Commons.

What the treatment is designed to do

Type 1 diabetes is an autoimmune condition in which the immune system attacks insulin-producing beta cells in the pancreas. Insulin helps move glucose from the bloodstream into cells, where it is used for energy. As beta-cell function declines, people with type 1 diabetes need insulin treatment and ongoing monitoring to manage blood glucose. Tzield is an immune-modulating medicine intended to delay the decline in the body’s own insulin production in the approved group. The FDA explains the newly approved use.

The agency said the accelerated approval was based on a controlled clinical trial showing a statistically significant effect on C-peptide, a marker used to assess the body’s insulin production. The FDA considers this marker reasonably likely to predict clinical benefit, but a post-approval study is still required to verify the treatment’s clinical benefit. This distinction is important: the approval supports a specific treatment effect, not a promise that every child will retain insulin production or avoid insulin therapy. FDA approval details and evidence.

Who may be eligible

The expanded indication applies to children aged 8 through 17 who have recently been diagnosed with Stage 3 type 1 diabetes. It is not a general treatment for all people with diabetes, and it is not intended for type 2 diabetes. A specialist must assess diagnosis, timing, health status and whether the treatment’s potential benefits outweigh its risks for an individual child. The FDA’s indication statement.

Safety information and limitations

Tzield carries important safety warnings. The FDA’s announcement notes a boxed warning about serious and potentially life-threatening viral reactivation, including Epstein-Barr virus and cytomegalovirus. Other reported side effects include vomiting, rash, headache and increased liver enzyme levels; reductions in white blood cells can also increase infection risk. Families should discuss the full prescribing information and monitoring requirements with the child’s diabetes care team. FDA safety information and the official DailyMed prescribing information provide further details.

HeadlinesXtra Discovery: The expanded approval represents progress in treatments that seek to modify the course of autoimmune disease rather than address symptoms alone. Its value will depend on careful patient selection, safety monitoring and the results of continuing follow-up research. It should be understood as a treatment that may delay the decline of insulin production in eligible children, not as a cure for type 1 diabetes.